HEK293-IL13RA2

305988

GENERAL INFORMATION

Description

□□□□□□□□□□□□□□□□□□□□/□□□□□□□□□□□□□□□□□□□6,250□□□
□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□

Tissue	□□□□
Disease	□□/□□□□□□□□□□HEK293□□□

Applications

□□IL13RA2□□□□CAR-T□□□□□□□□□□□□□□□□□□□□ADCC/CDC□□□□□□□□□□□□□□□□□□□

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This HEK293 cell line contains an IL13RA2 expression construct for cytokine receptor studies and targeted glioblastoma/mesothelioma therapy development. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Morphology	□□□
Cell type	□□□□
Doubling time	□24-36□□

IDENTIFIERS

Citation

HEK293-IL13RA2□Cytion □□ 305988□

NCBI TaxID	9606
Cellosaurus	CVCL_6G27

EXPRESSION AND SUSCEPTIBILITY

Receptors expressed

IL13RA2

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

HANDLING AND CULTURE

Culture medium

RPMI 1640□w□2.0 mM □□□□□□□w□2.0 g/L NaHCO3□Cytion □□□□ 820700a□□

Incubation atmosphere	37°C, 5%CO2, □□□□□

Supplements

□□□□□□□ 10% FBS□1 mM □□□□□10 mM HEPES □ 1% NEAA□□□□□□□G418-□□□□□□□□□□□□ 1 mg/mL□

Dissociation reagent	□□□□-EDTA

Subculturing

□□□□□□□□□□□□□□□□□□□□□□□□ PBS □□□□□□□□□□□□□□ PBS □□□□□□□□□□□□□□□□□□□/EDTA □□□□ T25 □□ 1 □□□T75 □□ 3 □□□□□□□ 37°C □□□□□□□□□5-10 □□□□□□□□□□□□□□□□□□□□

LEGAL AND SAFETY

Safety precautions

□□□